Vildagliptin also significantly decreased mean prandial glucose ( deltaLSM , -1.2 + / - 0.4 mmol/liter ; P = 0.01 ) and glucagon ( deltaLSM , -10.7 + / - 4.8 ng/liter ; P = 0.03 ) levels and increased plasma levels of intact GLP-1 ( deltaLSM , +10.8 + / - 1.6 pmol/liter ; P < 0.0001 ) and gastric inhibitory polypeptide ( deltaLSM , +43.4 + / - 9.4 pmol/liter ; P < 0.0001 ) relative to placebo .
